4:06 PM ET
8-K
Divestiture
Theriva Biologics Divestiture to Biossil Labs Inc.
Theriva Biologics completed the sale of its antibiotic-degrading enzyme portfolio, including SYN-004 (ribaxamase), to Biossil Labs Inc. for an upfront payment of $350,000. Theriva is eligible for up to $91 million in regulatory and sales milestones plus royalties, while Biossil assumes all future development costs and responsibilities.
- Counterparty
- Biossil Labs Inc.